



PROGRAMME

# New Zealand Skin Cancer Summit

# 2026

*Equity in action: bridging gaps for skin cancer*

**Friday 19 - Saturday 20 June 2026**

InterContinental Wellington • Aotearoa New Zealand



# Become a Founding Member of Skin Cancer NZ

Help fight skin cancer  
and save lives



## 2 in 3

New Zealanders  
will be diagnosed  
with skin cancer in  
their lifetime.

Skin cancer is New Zealand's most common cancer - and it can affect anyone. Yet up to 90% of skin cancers are preventable, and almost all are curable when caught early.

**This is where you can make a difference.**

As a Founding Member, you'll help shape skin cancer prevention, improve early detection, and support better care across New Zealand.

## Only 100 places available

Be part of Skin Cancer NZ from the beginning and help shape the future of skin cancer care in New Zealand.

Scan to join



**Join and help today**

### As a Founding Member, you will:



Support national prevention and early detection initiatives, and life-saving education.



Strengthen access and improve the quality of skin cancer care.



Make a lasting impact and be recognised for your support.



New Zealand's specialist  
skin cancer charity



hello@skincancer.org.nz



skincancer.org.nz

# Welcome

---

## We are delighted to welcome you to the 2026 New Zealand Skin Cancer Summit.

This Summit marks an exciting new chapter for our organisation. It is the first to be held under the Skin Cancer NZ name, and the first to cover all types of skin cancer.

Your participation reflects a shared commitment to improving skin cancer outcomes for all New Zealanders, so we thank you for making the time to be part of this important event.

We look forward to the conversations, connections, and outcomes that come from the Summit over the next two days, and to seeing their positive impact on skin cancer prevention, detection, treatment and support across Aotearoa New Zealand.



**Dr Susan Seifried**  
Chair, Skin Cancer NZ

## Our major supporters

---



MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, are unified around their purpose: they use the power of leading-edge science to save and improve lives around the world. For more than a century, they've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

---

## L'ORÉAL

Dermatological Beauty



L'Oréal Dermatological Beauty provides life-changing, sustainable solutions as the world leader in dermo-cosmetics. Featuring La Roche-Posay and CeraVe, their brands are recommended by healthcare professionals globally. Their ranges of science-backed products address pathological and aesthetic needs including sun protection, acne, eczema, and skin repair.

# Thank you to our generous supporters

---

## Silver



---

## Bronze



---

## Workshop



---

## Exhibitors




---

## Coffee cart



# Visit our trade exhibitors

- 01 MSD
- 02 L'Oréal Dermatological Beauty
- 03 Actor Pharmaceuticals
- 04 PolyNovo
- 05 Novartis
- 06 Skin Cancer Symposiums
- 07 NZ Skin Cancer Doctors' Society
- 08 HEINE Optotechnik
- 09 SolarCareB3
- 10 Skin Cancer College Australasia
- 11 Macquarie Medical Systems
- 12 Mölnlycke Health Care



# Explore the programme

---

Two days of expert insights, shared learning and discussion focused on improving skin cancer outcomes across New Zealand.

# Friday 19 June 2026

*Unless otherwise stated, all sessions are held in the Lambton Ballroom.*

## Welcome

**Chair: Dr Susan Seifried**

8.30 am **Mihi whakatau**

8.50 am **Opening address**

Hon Simeon Brown  
*Minister of Health*

9.00 am **Welcome and housekeeping**

Dr Susan Seifried  
*Chair, Skin Cancer NZ*

9.10 am **The role of coordinated care in achieving equity**

Associate Professor Alexander van Akkooi  
*Surgical Oncologist and Chair of Melanoma Surgical Oncology, Melanoma Institute Australia, Sydney*

9.40 am **A challenge to participants from a patient perspective**

Gareth Lester

10.00 am **Morning tea**

Pre-Function Lobby

## Session 1: A coordinated approach to prevention and early detection

**Chair: Dr Bronwen McNoe**

*This session is proudly supported by:*

**L'ORÉAL**  
Dermatological Beauty

**LAROCHE POSAY**  
LABORATOIRES DERMATOLOGIQUES

**CeraVe**  
Dermatological Care

10.30 am **Current direction and opportunities for skin cancer prevention**

Dr Nick Chamberlain  
*National Director, National Public Health Service, Health New Zealand | Te Whatu Ora*

10.55 am **Balancing the harms and benefits of sun exposure**

Professor Rachel Neale  
*Senior Group Leader, QIMR Berghofer Medical Research Institute, Brisbane*

---

11.20 am **Innovations in skin cancer early detection**  
Honorary Professor Amanda Oakley  
*Dermatologist and Honorary Professor at the University of Auckland and the University of Waikato*

---

11.45 am **Skin Cancer NZ AGM**

12.00 pm **Lunch** Pre-Function Lobby

**Session 2: Improving skin cancer outcomes in New Zealand**

**Chair: Dr Chris Boberg**

1.00 pm **Current and future skin cancer trials in New Zealand**  
Dr Gareth Rivalland  
*Medical Oncologist, Harbour Cancer & Wellness and Auckland City Hospital*

---

1.25 pm **Taking research from lab to clinic**  
Professor Cris Print  
*Professor of Molecular Medicine and Pathology, University of Auckland*

---

1.50 pm **Session 2 discussion**

**Session 3: Decoding skin cancer care**

**Chair: Dr Catherine Bennett**

2.00 pm **Demystifying radiotherapy**  
Dr Jeat Lee  
*Radiation Oncologist, Kathleen Kilgour Centre*

---

2.25 pm **Demystifying immunotherapy**  
Dr Lavinia Spain  
*Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne*

---

2.50 pm **Session 3 discussion**

3.00 pm **Afternoon tea** Pre-Function Lobby

**Session 4: Moving towards coordinated care models**

**Chair: Dr Susan Seifried**

3.30 pm **Skin cancer treatment pathways in primary care**  
Dr Keith Monnington  
*Skin Lesion Triage and Grading Clinician, Eastern Bay Primary Health Alliance and Western Bay of Plenty Primary Health Organisation Skin Lesion Services*

---

---

3.50 pm **Nelson Skin Cancer Service**

Dr Mark Fry

*General Practitioner with a special interest in skin cancer, Wakefield Health Centre and Nelson Bays Primary Health Organisation*

---

4.10 pm **The nurse's role in the pathway: helping to ease the skin cancer workload**

Rebecca Johnson

*National Melanoma Nurses Program Manager, Melanoma Institute Australia, Sydney*

---

4.30 pm **Session 4 discussion**

---

4.45 pm **Awards ceremony**

---

5.05 pm **Day 1 close**

Until 6.30 pm **Networking reception**

Pre-Function Lobby



# Skin cancer management & diagnosis made easy.

Fully accredited, highly practical skin cancer teaching by leading skin cancer experts - dermatoscopy made simple.

In person and online courses across New Zealand and Australia.

Find out more at [skincancersymposiums.com](http://skincancersymposiums.com)



# Saturday 20 June 2026

---

*Unless otherwise stated, all sessions are held in the Lambton Ballroom.*

## Session 5: Skin cancer management – Part 1

**Chair: Dr Alistair Brown**

- |         |  |
|---------|--|
| 8.00 am | <b>Day 2 welcome</b>   |
| 8.05 am | <b>From skin to scan... radiological staging and surveillance in melanoma and non-melanoma skin cancers</b><br>Dr Victoria Francis<br><i>Radiologist, Health NZ Waitemata and Canopy Imaging</i> |
| 8.25 am | <b>Role of topical treatments in pre-malignant and early skin cancer management</b><br>Dr Marc Lawrence<br><i>Dermatologist, Auckland Skin and Cancer Foundation</i>                             |
| 8.45 am | <b>Immunotherapy mechanism and resultant toxicity</b><br>Dr Lavinia Spain<br><i>Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne</i>   |
| 9.05 am | <b>Session 5 discussion</b>  |

## Session 6: Addressing challenging cases through clinical collaboration

**Chair: Mr Dan Butler**

- |         |   |
|---------|---|
| 9.30 am | <b>MDM panel case discussion: 'grey area' clinical scenarios</b><br><b>Panellists</b> <ul style="list-style-type: none"><li>• Associate Professor Alexander van Akkooi<br/><i>Surgical Oncologist and Chair of Melanoma Surgical Oncology, Melanoma Institute Australia</i></li><li>• Dr Ben Tallon<br/><i>Dermatologist, Dermatopathologist and Mohs Surgeon, SKIN Dermatology Institute</i></li><li>• Dr Jeat Lee<br/><i>Radiation Oncologist, Kathleen Kilgour Centre</i></li><li>• Dr Lavinia Spain<br/><i>Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne</i></li><li>• Dr Marc Lawrence<br/><i>Dermatologist, Auckland Skin and Cancer Foundation</i></li><li>• Dr Victoria Francis<br/><i>Radiologist, Health NZ Waitemata and Canopy Imaging</i></li></ul> |
|---------|---|

**Session 7: Concurrent sessions****Select one of the concurrent streams**

11.00 am

**7A: Borderline pigmented lesions**

Featherston Room

**Chair: Dr Alistair Brown**

This session will address the practical challenges of assessing borderline pigmented lesions. It will include an update from a pathologist and use real cases to explore diagnostic dilemmas and tricky clinical decisions.

**Presenters:**

- Dr Ben Tallon  
*Dermatologist, Dermatopathologist and Mohs Surgeon, SKIN Dermatology Institute*
- Professor Cliff Rosendahl  
*General Practitioner, University of Queensland, Brisbane*

**7B: Advanced melanoma management**

Rosanna Room

**Chair: Mr Dan Butler**

Designed for clinicians managing advanced melanoma, this interactive session will review real patient cases in a multidisciplinary meeting format. It will highlight recent advances in neoadjuvant melanoma care and BRAF-mutated melanoma and their interplay with surgical management, with a focus on practical clinical decision-making and multidisciplinary discussion.

**Presenters:**

- Associate Professor Alexander van Akkooi  
*Surgical Oncologist and Chair of Melanoma Surgical Oncology, Melanoma Institute Australia, Sydney*
- Dr Catherine Bennett  
*Medical Oncologist, Auckland City Hospital, Health NZ | Te Whatu Ora*
- Dr Jeat Lee  
*Radiation Oncologist, Kathleen Kilgour Centre*
- Dr Lavinia Spain  
*Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne*

---

## 7C: Nurses Special Interest Group

Lambton Ballroom

**Chair: Abbie Cameron**

This session will introduce the Skin Cancer Nurses Special Interest Group's work on a clinical guideline and care pathway for skin cancer nursing, focusing on how it supports best practice, role clarity, and high-quality patient care.

**Presenter:**

Rebecca Johnson

*Australia National Melanoma Nurses Programme Manager, Melanoma Institute Australia, Sydney*

---

12.00 pm

**Lunch**

Pre-Function Lobby

## Session 8: Skin cancer management – Part 2

**Chair: Mr Dan Butler**

---

1.00 pm

**Medical oncology advances in non-melanoma skin cancer**

Dr Catherine Bennett

*Medical Oncologist, Auckland City Hospital, Health NZ | Te Whatu Ora*

---

1.25 pm

**Neoadjuvant therapy from a surgeon's perspective**

Associate Professor Alexander van Akkooi

*Surgical Oncologist and Chair of Melanoma Surgical Oncology, Melanoma Institute Australia, Sydney*

---

1.50 pm

**The role of radiation therapy in skin cancer management**

Dr Jeat Lee

*Radiation Oncologist, Kathleen Kilgour Centre*

---

2.15 pm

**Session 8 discussion**

---

2.30 pm

**Afternoon tea**

Pre-Function Lobby

## Session 9: Tools and guidelines to empower best practice management

**Chair: Dr Chris Boberg**

---

3.00 pm

**Aotearoa New Zealand Melanoma Clinical Guidelines: defining best practice melanoma management in New Zealand**

Dr Susan Seifried

*General, Skin and Breast Oncological Surgeon, Nelson Hospital*

---

3.15 pm      **Non-melanoma skin cancer guidelines**  
Dr Neil Anderson  
*Skin Cancer Doctor, General Practitioner and Clinical Director, Coast to Coast Health Care*

---

3.30 pm      **Support services for patients**  
Abbie Cameron  
*Clinical Nurse Specialist*

---

3.45 pm      **Te Ao Mārama: equity in skin cancer care**  
Maarie Hutana  
*Registered Nurse and Māori Health & Health Equity Educator*

---

## **Session 10: Where to from here?**

**Chair: Dr Susan Seifried**

---

4.00 pm      **Panel discussion**

***Panellists:***

- Abbie Cameron  
*Clinical Nurse Specialist*
- Associate Professor Alexander van Akkooi  
*Surgical Oncologist and Chair of Melanoma Surgical Oncology, Melanoma Institute Australia*
- Dr Catherine Bennett  
*Medical Oncologist, Auckland City Hospital, Health NZ | Te Whatu Ora*
- Dr Jeat Lee  
*Radiation Oncologist, Kathleen Kilgour Centre*
- Dr Marc Lawrence  
*Dermatologist, Auckland Skin and Cancer Foundation*
- Dr Neil Anderson  
*Skin Cancer Doctor, General Practitioner and Clinical Director, Coast to Coast Health Care*
- Rebecca Johnson  
*Australia National Melanoma Nurses Programme Manager, Melanoma Institute Australia*

---

4.45 pm      **Wrap up and formal close**  
Dr Susan Seifried  
*Chair, Skin Cancer NZ*

---

5.00 pm      **Conference closes**

---

# E-poster presentations

---

- **Natural synergy in dermatological care: a multi-functional topical ointment for skin cancer and related lesions**  
Bijon Kumar Sil, Prince of Songkla University, Thailand
- **Are we missing melanoma follow-up? Surveillance adherence in a rural primary care cohort**  
Li Ning Yong, University of Auckland
- **Healing the heel**  
Emma Simpson, Nelson Hospital
- **Control over cure, a patient centred approach**  
Dr Phoebe Bardoul, Nelson Hospital
- **Margin of error: comparing efficacy of melanoma in-situ excision margins in the Manawatu region**  
Indira Fernando, Palmerston North Hospital
- **Clinical versus radiological melanoma surveillance in the Nelson Marlborough district**  
Khaleel Hamdulay, Nelson Hospital
- **Low incidence, high burden: melanoma inequities in Māori and Pacific peoples in Aotearoa New Zealand**  
Kate Bryant, University of Otago
- **Portable system for in-clinic differentiation of skin cancers from benign skin lesions**  
Michel Nieuwoudt, University of Auckland
- **Skin Cancer Nursing Practice Framework**  
Abbie Cameron, Skin Cancer NZ
- **SunSmart snapshot survey**  
Li Ning Yong, University of Auckland

# ANTHELIOS UVMUNE 400

## INVISIBLE FLUID SPF50+


**OUR BIGGEST REVOLUTION  
IN UV-PROTECTION IN 30 YEARS**

**MEXORYL 400 FILTERING THE MOST  
INSIDIOUS UV RAYS 340-400NM**


**PROTECTION AGAINST  
BROAD SPECTRUM UVB+UVA  
ULTRA-LONG UVA UP TO 400NM  
UVA-INDUCED PIGMENTATION**



UV FILTER SPECTRUM



**ENCIRCLES OIL AND UV FILTERS FOR A  
MORE HOMOGENOUS AND RESISTANT FILM  
THAT WONT MIGRATE INTO EYES AND STING**



CLASSICAL EMULSION  
VISUALISATION CSLM<sup>^</sup>



NETLOCK<sup>®</sup>  
TECHNOLOGY

<sup>^</sup>CSLM: Confocal Scanning Laser Microscopy. 25 µm thick deposit - 1 hour drying.

\*Based on a survey conducted among NZ Dermatologists, Pharmacists and General Practitioners by IQVIA, between November 2024 and February 2025.

Apply sunscreen 20 minutes before exposure. Sunscreen is only one part of sun protection, wear protective clothing and seek shade. Avoid prolonged sun exposure. Reapply every 2 hours or after swimming, towelling or perspiring.

This marketing material is intended for health professionals only and must not be distributed to patients or consumers as a substitute for medical advice or consultation with a health professional. We are not liable for any reliance the reader has on the information contained in this marketing material and accept no liability for any injury, loss or damage caused as a result.

# Meet our speakers

---

An exceptional faculty of clinicians, researchers and advocates from across Aotearoa New Zealand and Australia.

# Keynote speakers

---



## **Associate Professor Alexander van Akkooi**

**Melanoma Institute Australia, Sydney**

Alex is an internationally recognised surgical oncologist specialising in melanoma and cutaneous oncology. Born in the United States and trained in the Netherlands, he completed his MD at Erasmus University Medical Center, Rotterdam, and earned a PhD cum laude focused on sentinel node tumour load assessment in melanoma. He previously chaired the Melanoma and Skin Cancer Centre at the Netherlands Cancer Institute and served as Chair of the EORTC Melanoma Group. Since 2022, he has been Chair of Melanoma Surgical Oncology at Melanoma Institute Australia. He has published extensively, leads major clinical trials, and has expertise in melanoma staging, surgical de-escalation, and systemic therapies.



## **Professor Rachel Neale**

**QIMR Berghofer Medical Research Institute, Brisbane**

Rachel is a Senior Group Leader at QIMR Berghofer Medical Research Institute, where she leads a programme of research on balancing the harms and benefits of sun exposure. She completed her PhD nested within the seminal Nambour Trial, which showed that daily sunscreen application reduces the incidence of melanoma. She led the world's second-largest trial of high-dose vitamin D, and the only trial designed to examine the effect of high-SPF sunscreen application on vitamin D. Rachel is chair of the Health Working Group of a United Nations Environment Programme Panel, which delivers reports to the Parties to the Montreal Protocol on the environmental and health effects of ultraviolet radiation and sun exposure.



## **Rebecca Johnson**

**Melanoma Institute Australia, Sydney**

Rebecca is a clinical nurse consultant with experience across a range of nursing specialties, particularly cancer nursing. She completed a Bachelor of Health Sciences and Master of Nursing at the University of Sydney, and a Graduate Diploma in Nursing (Oncology) at the University of Tasmania. She previously worked at Melanoma Institute Australia (MIA) as a Melanoma Medical Oncology Clinical Nurse Consultant before moving to regional New South Wales, where she provided strategic oversight and guidance to the regional cancer service. She returned to MIA in 2023 as the Program Manager for the National Melanoma Nurses Program.



## **Dr Lavinia Spain**

**Peter MacCallum Cancer Centre, Melbourne**

Lavinia is a medical oncologist and Clinical Lead for melanoma within the Medical Oncology Department at Peter MacCallum Cancer Centre in Melbourne. She completed a Fellowship at the Royal Marsden NHS Foundation Trust in London and an MD(Res) through the Institute of Cancer Research in 2021. Her clinical and research interests include melanoma, immune-related adverse events, and tumour heterogeneity. She has published widely in this area, including international guidelines. Lavinia is a member of the ESMO Faculty of Investigational Immunotherapy and is actively involved in oncology education and training.



## Professor Cliff Rosendahl

University of Queensland, Brisbane

Professor Cliff Rosendahl is a general practitioner with over 50 years' experience. Over the past two decades, his work has focused on the early diagnosis of skin cancer and melanoma. In collaboration with colleagues in Brisbane and Vienna, he co-developed the diagnostic algorithms Chaos and Clues and Prediction Without Pigment. He is a Professor at the University of Queensland and a Distinguished Visiting Professor at Tehran University of Medical Sciences. Cliff has authored more than 110 peer-reviewed publications and two textbooks translated into multiple languages.



## Gareth Lester

Patient representative

Gareth Lester is a 43-year-old project manager for ANZ. He has been married to his wife Jane for 13 years and has a 9-year-old daughter, Hazel. Gareth was diagnosed with stage four melanoma in 2025. He has undergone multiple surgeries and is currently receiving immunotherapy. Gareth lives in Lower Hutt with his family and one very dependent cat. His interests include cooking, movies, gaming and playing Barbie dolls with Hazel. He has never liked too much sun, and apparently it doesn't like him either.



# LOWER COST SUTURES. SAME PERFORMANCE.

We stock a range of Demetech sutures to cover all of your skin cancer surgery needs



**LOWER COST SUTURES**  
For every procedure



**RELIABLE KNOT SECURITY**  
Consistent knot security



**CONSISTENT PERFORMANCE**  
Smooth handling. Better outcomes.



CONFERENCE OFFER  
**20% OFF**  
YOUR FIRST ORDER

Use code: **GP20**

Valid for conference attendees only.



WELCOME BACK OFFER  
**10% OFF**  
YOUR SECOND ORDER

Use code: **GP10**

Valid for conference attendees only.



ORDER ONLINE  
**rikimed.co.nz**

For samples contact  
info@rikimed.co.nz



## **Abbie Cameron**

### **Clinical Nurse Specialist, skin cancer**

Abbie is a clinical nurse specialist in skin cancer with 10 years' experience across hospital, community, charity, and private sector care. She holds a Diploma in Dermoscopy, chairs the Skin Cancer Nurses' Special Interest Group, and contributes to the National Melanoma Working Group for the Aotearoa New Zealand Melanoma Clinical Guidelines.



## **Honorary Professor Amanda Oakley**

### **Creator of DermNet; CNZM**

Amanda is a dermatologist who has recently retired from Health New Zealand | Te Whatu Ora Waikato. Trained in Auckland, London and Durham (UK), she has been a consultant in Waikato since 1987. She is the creator of DermNet and was appointed a Companion of the New Zealand Order of Merit in 2018 for services to dermatology. She has published extensively and has a strong interest in teledermatology, medical education, and improving equitable access to care through digital innovation and artificial intelligence.



## **Dr Catherine Bennett**

### **Auckland City Hospital; Harbour Cancer & Wellness**

Catherine is a medical oncologist with special interest in melanoma, skin and head and neck cancer. She works at both Auckland City Hospital, where she is clinical lead for the head and neck cancer team, and at Harbour Cancer and Wellness. Catherine completed her specialist training in medical oncology in Auckland, before undertaking a fellowship in head and neck, melanoma and skin cancer at Peter MacCallum Cancer Centre in Melbourne. During her fellowship she was an investigator in numerous clinical trials of novel therapeutic approaches to these cancers and gained considerable experience using immunotherapy.



## **Professor Cris Print**

### **University of Auckland**

Cris is a Professor in Molecular Medicine and Pathology at the University of Auckland. He leads a cross-disciplinary team of clinicians, biologists and data scientists who use genomics and related technologies to better understand cancer, including melanoma. He also chairs the Scientific Board of the Auckland Regional Biobank and leads the Genomics into Medicine Strategic Research Initiative. Cris graduated in medicine from the University of Auckland in 1989, then completed a PhD in molecular immunology, followed by postdoctoral training at the Walter and Eliza Hall Institute in Melbourne. Cris then moved to Cambridge University, UK, where he was a fellow of St Edmund's College and co-founded a genomics biotechnology company.



## Dr Gareth Rivalland

**Harbour Cancer & Wellness; Auckland City Hospital**

Gareth is a medical oncologist specialising in the treatment of melanoma and skin cancers. He works at both Harbour Cancer & Wellness and Auckland City Hospital, where he is the melanoma team lead. He has been the principal investigator in numerous global clinical trials.



## Dr Jeat Lee

**Kathleen Kilgour Centre**

Jeat is a radiation oncologist at the Kathleen Kilgour Centre in Tauranga. He has expertise in the treatment of skin, head and neck, central nervous system, and gastrointestinal malignancies, and a special interest in stereotactic ablative body radiotherapy (SABR) in both curative and palliative settings. He is a member of the Bay of Plenty regional skin multidisciplinary meeting and contributed to the radiation oncology sections of the recently updated Aotearoa New Zealand Melanoma Clinical Guidelines.



## AI-POWERED TO SUPPORT EARLIER MELANOMA DETECTION

**SKINTRACKER™** offers your patients access to AI-supported skin monitoring with comprehensive total body imaging and comparative tracking over time - smarter skin surveillance and earlier detection.

**Available now across Auckland, as well as in Wellington, Richmond & Queenstown.**

**Referrals welcome.  
EDI: skininst**



**Scan for more information**



**SKIN INSTITUTE**

EXPERTS IN SKIN, VEINS & APPEARANCE MEDICINE



## **Dr Keith Monnington**

### **Skin Cancer College Australasia**

Keith is a retired general practitioner. His practice was predominantly focused on skin cancer from 2009 to 2021. He is a former Director and President of the Skin Cancer College Australasia (SCCA) and served as a presenter and tutor for SCCA courses from 2013 to 2023. He was involved in setting up the Bay of Plenty Skin Lesion Service in 2007, worked as a contracted GP with a special interest from 2007 to 2021, and has also served as a triage and grading clinician since 2013.



## **Maarie Hutana**

### **Ngāi Tahu — Independent Māori Health Educator and Advisor**

Maarie is a health educator and nurse specialising in Māori health, equity, and culturally safe clinical practice. A former haematology cancer nurse, she has worked across national and local settings to strengthen system responsiveness for Māori. She previously served as Māori Engagement Manager at Te Tāhū Hauora Health Quality & Safety Commission. In this role, she supported the integration of Te Tiriti o Waitangi and mātauranga Māori within a national programme that worked in partnership with Māori communities. Maarie now works independently as an educator and advisor, delivering Māori health, cultural safety, and equity-focused education across Aotearoa.

## **Dr Marc Lawrence**

### **Auckland Skin & Cancer Foundation**



Marc is an Auckland-based consultant dermatologist, Mohs surgeon, and laser specialist. He practises at the Auckland Skin & Cancer Foundation, specialising in Mohs micrographic surgery and the management of complex skin cancers. Marc trained in New Zealand and the UK, including at the Royal Victoria Infirmary in Newcastle. He is a Fellow of the New Zealand Dermatological Society and the Royal Australasian College of Physicians.



## **Dr Mark Fry**

### **Wakefield Health Centre**

Mark is a New Zealand-trained general practitioner who splits his time between skin cancer medicine and surgery, and general practice. Based at the Wakefield Health Centre near Nelson, Mark also does some rural practice in Murchison and the Chatham Islands. Since 2013, he has worked as the GP Advisor for the Nelson Bays Skin Cancer Service and has been Skin Cancer College Australasia accredited since 2017. He has been performing intermediate level skin cancer procedures since 2018.



## **Dr Neil Anderson**

### **Coast to Coast Healthcare; New Zealand Skin Cancer Doctors**

Neil is a general practitioner with a special interest in skin cancer medicine and surgical management. Based in Wellsford, he has been excising skin cancers at Coast to Coast Healthcare since 2012 and operates under the Waitematā General Practice referral scheme. Initially trained in Edinburgh, Scotland, Neil has completed certificates in advanced dermoscopy and surgical skills. He is actively involved in education and training, including teaching medical students from the University of Auckland on clinical attachment to his practice. Neil has been involved in the Executive Committee of New Zealand Skin Cancer Doctors for several years and coordinates its regular education sessions.



## **Dr Nick Chamberlain**

### **National Public Health Service, Health New Zealand | Te Whatu Ora**

Nick holds the position of National Director for the National Public Health Service at Health New Zealand | Te Whatu Ora. Previously he was Northland District Health Board (DHB) Chief Executive for nearly 12 years, and the National DHB CEO Lead for Primary Care and Public Health. Nick has specialist qualifications in Medical Administration and General Practice. He has previously held roles as General Manager of Clinical Services at Northland DHB, General Manager of Planning and Funding at Capital & Coast DHB, and Clinical Advisor and GP Liaison at Northland DHB, along with 11 years as a General Practitioner.



## **Dr Susan Seifried**

### **Skin Cancer NZ; Nelson Hospital**

Susan is a general surgeon specialising in skin and breast oncological surgery, based in Nelson. She was the Poche Fellow at the Melanoma Institute of Australia in 2009, and is a founding member and now Chair of the National Melanoma Working Group, who wrote and maintain the Aotearoa New Zealand Melanoma Clinical Guidelines (previously Quality Statements). She is also Chair of the Skin Cancer NZ Executive and a new director on the Melanoma and Skin Cancer Clinical Trials Board.



## **Dr Victoria Francis**

### **Health NZ | Te Whatu Ora Waitematā**

Victoria is a radiologist with a special interest in melanoma, based in Auckland. In her role at Health New Zealand | Te Whatu Ora Waitematā, she has served as the lead radiologist for the regional melanoma multidisciplinary meeting for several years. She has also been a longstanding member of the National Melanoma Working Group, responsible for the development and maintenance of the Aotearoa New Zealand Melanoma Clinical Guidelines.

# Session chairs and panellists



## Dr Ben Tallon

**SKIN Dermatology Institute; Pathlab Tauranga**

Ben is a dermatologist and dermatopathologist who works at SKIN Dermatology Institute and Pathlab Tauranga. His areas of special interest include skin cancer, Mohs surgery, cutaneous lymphoma, inflammatory skin conditions and dermatopathology. He graduated from the University of Auckland School of Medicine in 1999 and completed specialist training in Dermatology in Auckland, followed by fellowships in dermatopathology in Boston, USA, and at the University of Graz, Austria.



## Dr Bronwen McNoe

**University of Otago**

Bronwen is a researcher at the University of Otago. She is co-director of the Social and Behavioural Research Unit and leads the skin cancer prevention component of the research collaboration between the University of Otago and the Cancer Society. She has more than 30 years of experience in public health research, particularly focusing on the primary prevention of skin cancer and occupational injury.



Now funded in New Zealand<sup>1,2\*</sup>



# Target Early Treat Confidently

For your patients with adjuvant or metastatic *BRAF* V600-positive melanoma.<sup>3,4†</sup>



Patient example.  
Not a real patient.

\*Eligibility criteria apply. Please refer to [www.pharmac.govt.nz](http://www.pharmac.govt.nz) for full Special Authority Criteria.<sup>1,2</sup>

†Tafinlar + Mekinist in combination is indicated for the treatment of patients with unresectable (Stage III) or metastatic (Stage IV) melanoma, or adjuvant Stage III melanoma following complete resection, and with a *BRAF* V600 mutation.<sup>3,4</sup>

**PRESCRIPTION MEDICINE. TAFINLAR® (dabrafenib mesilate)** 50 mg and 75 mg hard gelatin capsules and **MEKINIST® (trametinib dimethyl sulphoxide)** 0.5 mg and 2 mg film coated tablets. Indications: Adjuvant treatment of patients with Stage III melanoma with a *BRAF* V600 mutation, following complete resection. Treatment of patients with *BRAF* V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma. Consult full Data Sheet before prescribing, (available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz)), for information on dosage, contraindications, precautions, interactions and adverse effects. Tafinlar in combination with Mekinist is funded under Special Authority Criteria from June 1<sup>st</sup> 2025 for adjuvant treatment of patients with Stage III melanoma with a *BRAF* V600 mutation following complete resection, and unresectable or metastatic melanoma with a *BRAF* V600 mutation, please refer to [www.pharmac.govt.nz](http://www.pharmac.govt.nz).

**References:** 1. Pharmaceutical Schedule. SA2494. Available at: [www.pharmac.govt.nz](http://www.pharmac.govt.nz) (Accessed August 2025). 2. Pharmaceutical Schedule. SA2496. Available at: [www.pharmac.govt.nz](http://www.pharmac.govt.nz) (Accessed August 2025). 3. Tafinlar (dabrafenib) Data Sheet. 4. Mekinist (trametinib) Data Sheet.

© Registered Trademark of Novartis AG. Novartis New Zealand Limited, Auckland. Ph 0800 354 335. NZ-01720. TAPS MR12359. August 2025. NVR-13726.

NOVARTIS



**Mr Dan Butler**  
**Consultant Plastic Surgeon**

Dan is a Consultant Plastic Surgeon in the Bay of Plenty with both public and private practice. He trained in the UK, including a 12-month fellowship in head, neck, and skin cancer management. He established and chairs the Bay of Plenty skin cancer multidisciplinary meeting and contributes to the National Melanoma Working Group.



**Dr Alistair Brown**  
**Skin Centre Tauranga**

Alistair is a consultant dermatologist at the Skin Centre in Tauranga with public hospital roles across the region. He trained in the UK, completing a fellowship in Mohs surgery. Since returning to New Zealand, Alistair has contributed to the Aotearoa New Zealand Melanoma Clinical Guidelines and established a renal transplant skin cancer surveillance clinic.



**Dr Chris Boberg**  
**SkinCheck Ltd; President, NZ Skin Cancer Doctors Society**

Chris is a highly experienced general practitioner with a special interest in skin cancer. He is President of the New Zealand Skin Cancer Doctors Society, a former Executive member of MelNet (2013–2025), Director of Skin Cancer Symposiums Ltd and partner at SkinCheck Ltd. Chris is widely recognised for his commitment to teaching, mentoring, and supporting clinicians to develop confidence and expertise in skin cancer medicine.



The New Zealand Skin Cancer Doctors' Society (NZSCD) was formed in 2017 to provide opportunities for collaboration, credentialing, ongoing education and professional support for all healthcare providers involved in the diagnosis and/or the management of cutaneous malignancies.

In recent years, Healthcare funders (primarily Medical Insurance companies) are recognising the credentialing process that the NZSCD Society has implemented prior to members becoming Full Members. Those providers who gain Full Membership are accepted by most medical insurance companies to be covered via the specialist portion of their insurance policies.

**Benefits of NZSCD membership include:**

- Engagement and lobbying on behalf of our members and their patients
- Validations of standards of care
- WhatsApp discussion forum, peer groups, mentoring contacts
- Educational events, and networking opportunities

With 3 levels of membership, we welcome all Skin Cancer Professionals:

- **Full Member:** Experienced Skin Cancer Doctor
- **Associate Member:** Doctor with Interest in Skin Cancer
- **Affiliate Member:** Nurse, Nurse Dermoscopist, Allied Health Professional

Please visit our website: [www.nzscd.org.nz](http://www.nzscd.org.nz) for membership details



**Melanoma and Skin Cancer Trials**  
Limited



**AMC 2026**  
Australasian Melanoma Conference

# SCIENTIFIC MEETING 2026

*Collaborating to eliminate  
melanoma and skin cancer*

**19 November**  
The Sofitel  
Melbourne,  
Australia

**Register  
now:**



## **Influence clinical research - Join our DSA's**

Our Discipline-Specific Advisories (DSAs) create a forum for researchers and health care professionals to share ideas and drive progress through collaboration to improve outcomes for patients with melanoma and skin cancer.

### **Benefits:**

- Access peer review, mentoring and collaboration from experienced clinical trialists
- Clear pathway to endorsement from MASC Trials
- Receive latest news from our clinical trial portfolio

- Dermatology
- Medical & Radiation Oncology
- Skin Cancer
- Nursing, Allied Health, Public Health & Primary Care
- Surgical Oncology
- Australasian Merkel Cell Research Interest Group
- Australian Ocular Melanoma Alliance

**FREE AND EASY TO APPLY | E: [grants@masc.org.au](mailto:grants@masc.org.au)**

**FOR MORE INFO: [masc.org.au/discipline-specific-advisories/](https://masc.org.au/discipline-specific-advisories/)**



**Melanoma  
and Skin  
Cancer Trials**  
Limited

# General information

---

## Mobile phones

Please ensure mobile phones are switched off or set to silent during all conference sessions.

## Name badge

Please wear your name badge at all times during the Summit.

## Conference Wi-Fi

Complimentary Wi-Fi is available for conference delegates.

Network: IHGWiFi.com  
Select Connect to Wifi  
Select the Access Code Icon  
Password: Wellington2026

## Continuing Medical Education

All delegates will receive a certificate of attendance in the weeks following the Summit.

The event has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and approved for up to 26 CME credits for Continuing Professional Development (CPD) purposes.

Credits for active RNZCGP Fellows will be uploaded automatically where RNZCGP details were provided at registration. All other attendees will need to self-report their CME credits.

## Tell us what you thought

Your feedback is important and helps shape future educational events. Please complete the evaluation survey at the conclusion of the Summit by scanning the QR code below.



## Disclaimer

The programme was correct at the time of publication, however minor changes may occur during the event and will be communicated to delegates.

## Photography

Photography will take place during the Summit. These images may be used by Skin Cancer NZ for educational or promotional purposes.

## Acknowledgements

The Skin Cancer NZ Executive and Summit Planning Committee thank all speakers, chairs and panellists for generously giving their time and expertise. We also acknowledge our sponsorship partners whose support has made this event possible.

### Skin Cancer NZ Executive

Dr Susan Seifried (Chair)  
Dr Sam Mayhew (Deputy Chair)  
Abbie Cameron  
Dr Alistair Brown  
Mr Dan Butler  
Mr Gary Duncan  
Julie Moon  
Karen Warman  
Renata Krzyszycha

### Summit Planning Committee

Dr Susan Seifried  
Dr Chris Boberg  
Mr Dan Butler  
Dr Jeat Lee  
Dr Sam Mayhew

### Organising Committee

Marion Peat  
Katrina Patterson





*Equity in action: bridging gaps for skin cancer*

**New Zealand  
Skin Cancer Summit**

Friday 19 - Saturday 20 June 2026

InterContinental Wellington

Aotearoa New Zealand